摘要
目的 探讨高血压病患者牙龈增生与服用钙拮抗剂的关系 ,为预防药物性牙龈增生提供临床依据。方法 采用随机整群的抽样方法 ,对武汉市 5 6个机关单位的 95 0例高血压病患者进行问卷调查和体检。结果 服用钙拮抗剂组牙龈增生的患病率为 4 9 6 8% (15 8 318) ,明显高于未服用钙拮抗剂组的 1 4 3% (9 6 32 )。在服药 6、12、2 4个月时牙龈增生指数分别为 (40± 5 ) %、(41± 6 ) %和(44± 11) % ;36个月后为 (30± 7) %。服用钙拮抗剂者年龄与牙龈增生患病率呈负相关 ,相关系数为- 0 72 5 (P <0 0 5 ) ,钙拮抗剂单一用药组和联合用药组牙龈增生患病率分别为 77 5 %和 33 0 % ,两者间有显著性差异 (P <0 0 5 )。结论 高血压病患者牙龈增生与服用钙拮抗剂持续的时间、方式及年龄有一定相关性 ,提示联合用药方式是减少高血压病患者药物性牙龈增生的有效途径。
Objective To investigate the relationship between calcium antagonists(CAS) and gingival hyperplasia in hypertensive patients and to provide clinical evidences for preventing drug induced gingival hyperplasia Methods In the 56 government organizations of Wuhan City, 950 hypertensive patients were investigated with a chester random sampling method Results The prevalence rate of gingival hyperplasia was 49 68% in CAS administered group, which was significantly higher than that (1 43%) in non CAS administered group Hyperplasia indices were (40±5)%, (41±6)% and (44±11)% in 6, 12, 24 months after administration of CAS, then slowly decreased to (30±7)% in three years There was a negative correlation between prevalence rate of gingival hyperplasia and the age of patients who took CAS ( r = 0 725; P <0 05) The prevalence rate of gingival hyperplasia in administration of CAS alone group was 77 5%,whereas it was 33% in combined administration group The difference between the two groups was highly significant ( P <0 05) Conclusion The gingival hyperplasia is associated with the factors of therapy duration, administration method and the age of those hypertensive patients The combined administration provides an effective way for avoidance of the drug induced gingival hyperplasia
出处
《中华心血管病杂志》
CAS
CSCD
北大核心
2002年第9期535-537,共3页
Chinese Journal of Cardiology
关键词
高血压
牙龈增生
钙拮抗剂
相关性研究
Hypertension
Gingival overgrowth
Calcium channel blockers
